Literature DB >> 17699495

Current management of vascular access.

Michael Allon1.   

Abstract

Optimizing vascular access outcomes remains an ongoing challenge for clinical nephrologists. All other things being equal, fistulas are preferred over grafts, and grafts are preferred over catheters. Mature fistulas have better longevity and require fewer interventions, as compared with mature grafts. The major hurdle to increasing fistula use is the high rate of failure to mature of newly created fistulas. There is a desperate need for enhanced understanding of the mechanisms of failure to mature and the optimal type and timing of interventions to promote maturity. Grafts are prone to frequent stenosis and thrombosis. Surveillance for graft stenosis with preemptive angioplasty may reduce graft thrombosis, but recent randomized clinical trials have questioned the efficacy of this approach. Graft stenosis results from aggressive neointimal hyperplasia, and pharmacologic approaches to slowing this process are being investigated in clinical trials. Catheters are prone to frequent thrombosis and infection. The optimal management of catheter-related bacteremia is a subject of ongoing debate. Prophylaxis of catheter-related bacteremia continues to generate important clinical research. Close collaboration among nephrologists, surgeons, radiologists, and the dialysis staff is required to optimize vascular access outcomes and can be expedited by having a dedicated access coordinator to streamline the process. The goal of this review is to provide an update on the current status of vascular access management.

Entities:  

Mesh:

Year:  2007        PMID: 17699495     DOI: 10.2215/CJN.00860207

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  83 in total

1.  Clinical management of dialysis catheter-related bacteremia with concurrent exit-site infection.

Authors:  Dmitri Sychev; Ivan D Maya; Michael Allon
Journal:  Semin Dial       Date:  2011 Mar-Apr       Impact factor: 3.455

2.  Clinical analysis of hemodialysis vascular access: comparision of autogenous arterioveonus fistula & arteriovenous prosthetic graft.

Authors:  Duk-Sil Kim; Sung-Wan Kim; Jun-Chul Kim; Ji-Hyung Cho; Joon-Hyuk Kong; Chang-Ryul Park
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2011-02-12

3.  Statin therapy is not associated with improved vascular access outcomes.

Authors:  Roberto Pisoni; Jill Barker-Finkel; Michael Allo
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 8.237

4.  Association of factor V gene polymorphism with arteriovenous graft failure.

Authors:  Michael Allon; Li Zhang; Ivan D Maya; Molly S Bray; Jose R Fernandez
Journal:  Am J Kidney Dis       Date:  2012-01-24       Impact factor: 8.860

5.  Fistula first: recent progress and ongoing challenges.

Authors:  Michael Allon
Journal:  Am J Kidney Dis       Date:  2011-01       Impact factor: 8.860

6.  Novel paradigms for dialysis vascular access: Introduction.

Authors:  Michael Allon
Journal:  Clin J Am Soc Nephrol       Date:  2013-12       Impact factor: 8.237

7.  Technical aspects of the mouse aortocaval fistula.

Authors:  Kota Yamamoto; Xin Li; Chang Shu; Tetsuro Miyata; Alan Dardik
Journal:  J Vis Exp       Date:  2013-07-11       Impact factor: 1.355

8.  Long-Term Outcomes of Arteriovenous Fistulas with Unassisted versus Assisted Maturation: A Retrospective National Hemodialysis Cohort Study.

Authors:  Timmy Lee; Joyce Zhang Qian; Yi Zhang; Mae Thamer; Michael Allon
Journal:  J Am Soc Nephrol       Date:  2019-10-14       Impact factor: 10.121

9.  Induction of heme oxygenase-1 is a beneficial response in a murine model of venous thrombosis.

Authors:  Michal J Tracz; Julio P Juncos; Joseph P Grande; Anthony J Croatt; Allan W Ackerman; Zvonimir S Katusic; Karl A Nath
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

Review 10.  Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: Cells, biomaterials, and devices.

Authors:  Shang Song; Shuvo Roy
Journal:  Biotechnol Bioeng       Date:  2016-01-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.